[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nstemi---non-st-segment-elevation-myocardial-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nstemi---non-st-segment-elevation-myocardial-infarction":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100641603","abbreviated-antithrombotic-therapy-after-pci-in-patients-with-af-and-ami-100641603",false,"NCT07583784","Abbreviated Antithrombotic Therapy After PCI in Patients With AF and AMI","Heart-team for Evidence-based RevascularizatiOn: Abbreviated Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Acute Myocardial Infarction","HERO-AF-AMI","Inclusion Criteria:\n\n1. Patients aged 19 years old\n2. Patients with AF and CHA2DS2-VA score ≥2.\n3. ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI)\n\n   * STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block.12\n   * NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:12\n\n     1. Symptoms of ischemia.\n     2. New or presumed new significant ST-T wave changes\n     3. Development of pathological Q waves on electrocardiography.\n     4. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.\n     5. Intracoronary thrombus detected on angiography.\n4. Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment.\n\nExclusion Criteria:\n\n1. Patients contraindicated for use of DOACs or clopidogrel\n2. Mechanical prosthetic valve or moderate-to-severe mitral stenosis requiring vitamin K antagonist\n3. Planned cardiac surgery within 1 year after randomization\n4. Patients with severe thrombocytopenia or coagulopathy\n5. Liver cirrhosis or severe hepatic dysfunction\n6. Advanced chronic kidney disease (creatinine clearance \\\u003C15 ml\u002Fmin\u002F1.73 m2) or on dialysis\n7. Prior history of intracranial hemorrhage\n8. Coexisting conditions related to high risk of life-threatening bleeding\n9. Pregnancy or breast feeding\n10. Non-cardiac co-morbid conditions are present with life expectancy \\\u003C1 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n11. Unwillingness or inability to comply with the procedures described in this protocol.","ALL","19 Years",{"count":20,"type":21},860,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of the study is to compare clinical outcomes between direct oral anticoagulant (DOAC) monotherapy versus dual antithrombotic therapy (DOAC plus clopidogrel) in patients with atrial fibrillation and acute myocardial infarction after percutaneous coronary intervention (PCI).",[27,28,29,30],"Myocardial Infarction (MI)","ST-Segment Elevation Myocardial Infarction(STEMI)","NSTEMI - Non-ST-Segment Elevation Myocardial Infarction","AF - Atrial Fibrillation",[32,33,34,35,36,37,38],"AF","Myocardial infarction","STEMI","NSTEMI","DOAC","NOAC","OAC alone","NOT_YET_RECRUITING","2026-06-15",{"date":42,"type":43},"2026-06-17","ACTUAL",{"date":45,"type":21},"2026-07-01",{"date":47,"type":21},"2032-12-31",{"name":49,"class":50},"Chonnam National University Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":51},"100639617","the-core---fr-clinical-trial-100639617","NCT07598565","The CORE - μFR Clinical Trial","μFR -Guided Complete Revascularization in Patients With Acute Coronary Syndromes","Inclusion Criteria:\n\n1. Patients presenting with ACS within 72 hours of successful culprit PCI\n2. Residual coronary artery disease, defined as at least one additional stenosis in any non-culprit vessel (NCV) with the following characteristics:\n\n   1. at least 50% diameter stenosis by visual assessment\n   2. a vessel diameter of at least 2.5 mm\n   3. amenable to successful PCI\n\nExclusion Criteria:\n\n1. Cardiogenic shock or severe heart failure (NYHA class ≥III)\n2. Severely impaired renal function: creatinine \\>2 mg\u002Fdl or estimated glomerular filtration rate (eGFR) \\\u003C30 ml\u002Fmin\u002F1,73 m²\n3. Allergy to iodine-containing contrast agents which cannot be adequately pre-medicated\n4. Pregnancy or intention to become pregnant during the trial\n5. Life expectancy less than one year\n6. Ambiguity in the identification of the culprit vessel\u002Flesion\n7. Clinical presentation as myocardial infarction and non-obstructive coronary artery disease (MINOCA) and\u002For Tako-Tsubo Syndrome\n8. Any ambiguity in the diagnosis of ACS\n9. Inability to provide informed consent\n10. Patients with only one coronary artery lesion with diameter stenosis \\>90% and\u002For TIMI flow \\\u003C3\n11. Patients in whom the NCV is treated at the time of the index procedure\n12. An interrogated lesion is at the site of a myocardial bridge\n13. An interrogated lesion is a culprit lesion responsible for the acute myocardial infarction\n14. An interrogated lesion is in a bypass graft\n15. Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification\n16. Severe vessel overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to μFR measurement",{"count":60,"type":21},350,[24],"Acute coronary syndromes (ACS) are frequently associated with multivessel coronary artery disease (CAD), and current guidelines recommend complete revascularization beyond the culprit lesion. Angiography-guided PCI is the standard approach, but anatomical assessment does not always reflect the functional significance of intermediate lesions, while FFR-guided strategies are limited by the need for pressure wires and hyperemia. Murray-law-based quantitative flow ratio (μFR) is a wire-free angiography-derived physiological index that may improve decision-making for revascularization in ACS patients.\n\nThe Core-μFR is an investigator-driven, multicenter, randomized, open-label and prospective trial designed to evaluate whether μFR can act as a gatekeeper for complete revascularization in patients with ACS and multivessel disease by identifying non-culprit lesions that truly require PCI.\n\nPatients with ACS (either STEMI or NSTE-ACS) undergoing primary PCI will be considered eligible if they present multivessel CAD on visual assessment with the intention to treat the non-culprit vessel in a staged procedure within the same hospitalization. After the pPCI, eligible patients will be randomized to either group A or group B and μFR will be performed in a blinded fashion with the operator unaware of the functional result. Patients in group A will undergo a staged PCI of all NCVs guided by coronary angiography, as per standard of care. In group B, μFR will be used as a gatekeeper for staged revascularization. Operators will only be informed whether at least one non-culprit vessel is μFR-positive, without disclosure of the specific vessel involved or the μFR values. If at least one non-culprit vessel has μFR ≤0.80, patients will undergo angiography-guided PCI of all non-culprit vessels previously deemed suitable for treatment by visual assessment. If μFR is \\>0.80 in all non-culprit vessels, staged PCI will be deferred and the patient will be discharged without further revascularization. Finally, to test the functional reproducibility, a blinded post-hoc μFR assessment will be performed on the baseline angiograms of the staged procedures in all the patients undergoing complete revascularization. Clinical follow-up will be performed at 30 days and 1 year from randomization.",[64,29,65,66],"Acute Coronary Syndromes (ACS)","STEMI - ST Elevation Myocardial Infarction","Multivessel Coronary Artery Disease",[68,69,70],"Murray-law based Quantitative Flow Ratio (μFR)","Non culprit vessel","Revascularization","2026-05-19",{"date":73,"type":43},"2026-05-22",{"date":75,"type":21},"2026-05-18",{"date":77,"type":21},"2028-06-30",{"name":79,"class":50},"University of Roma La Sapienza"]